The US Food and Drug Administration (FDA) has approved Lupin's abbreviated new drug application (ANDA) for its Ceftriaxone injection in 10mg vials, according to an official release issued by the compnay to the BSE today."The approval of our Ceftriaxone 10mg ANDA completes the entire Ceftriaxone product family," Kamal Sharma, MD of Lupin, said.With this approval, the company now has 15 ANDAs approved by the US FDA. Ceftriaxone is the generic equivalent of Rocephin marketed by Roche.
